OTCMKTS:PFND

Pathfinder Cell Therapy Stock Forecast, Price & News

$0.01
0.00 (0.00 %)
(As of 05/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.01
$0.01
50-Day Range
$0.01
$0.01
52-Week Range
$0.00
$0.03
VolumeN/A
Average Volume88,835 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Beta-0.62
30 days | 90 days | 365 days | Advanced Chart
Receive PFND News and Ratings via Email

Sign-up to receive the latest news and ratings for Pathfinder Cell Therapy and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PFND
CUSIPN/A
CIKN/A
Phone617-245-0289
Employees1
Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Headlines

See More Headlines

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.

MarketRank

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1944th out of 2,041 stocks

Surgical Appliances & Supplies Industry

39th out of 40 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Pathfinder Cell Therapy (OTCMKTS:PFND) Frequently Asked Questions

What stocks does MarketBeat like better than Pathfinder Cell Therapy?

Wall Street analysts have given Pathfinder Cell Therapy a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pathfinder Cell Therapy wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Pathfinder Cell Therapy's key executives?

Pathfinder Cell Therapy's management team includes the following people:
  • Mr. Joerg Gruber, Founder & Chairman (Age 60, Pay $20k)
  • Dr. Richard L. Franklin, Founder, CEO, Pres, Sec. & Exec. Director (Age 76, Pay $120k)
  • Mr. John M. Benson, CFO & Treasurer (Age 59, Pay $119k)

Who are some of Pathfinder Cell Therapy's key competitors?

What is Pathfinder Cell Therapy's stock symbol?

Pathfinder Cell Therapy trades on the OTCMKTS under the ticker symbol "PFND."

How do I buy shares of Pathfinder Cell Therapy?

Shares of PFND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pathfinder Cell Therapy's stock price today?

One share of PFND stock can currently be purchased for approximately $0.01.

How many employees does Pathfinder Cell Therapy have?

Pathfinder Cell Therapy employs 1 workers across the globe.

What is Pathfinder Cell Therapy's official website?

The official website for Pathfinder Cell Therapy is www.pathfindercelltherapy.com.

Where are Pathfinder Cell Therapy's headquarters?

Pathfinder Cell Therapy is headquartered at 12 Bow Street, Cambridge MA, 02138.

How can I contact Pathfinder Cell Therapy?

Pathfinder Cell Therapy's mailing address is 12 Bow Street, Cambridge MA, 02138. The company can be reached via phone at 617-245-0289.


This page was last updated on 5/7/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.